Publication: Quinolones and multidrug-resistant tuberculosis
Issued Date
1999-08-06
Resource Type
ISSN
00093157
Other identifier(s)
2-s2.0-0032818617
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Chemotherapy. Vol.45, No.SUPPL. 2 (1999), 12-18
Suggested Citation
Khun Nanta Maranetra Quinolones and multidrug-resistant tuberculosis. Chemotherapy. Vol.45, No.SUPPL. 2 (1999), 12-18. doi:10.1159/000048477 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/25604
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Quinolones and multidrug-resistant tuberculosis
Author(s)
Other Contributor(s)
Abstract
The prevalence of initial resistance of multidrug-resistant tuberculosis (MDR-TB) to at least isoniazid (INH) and rifampicin (RFP) in Thailand during the period 1993-1997 is reported; in this era, trends for INH + RFP + streptomycin (SM) and ethambutol (EMB), INH + RFP + SM or EMB and MDR-TB were stable. The prevalence of acquired MDR-TB is on a slight downward trend, with the latest level at 22.6%. Recommended management of MDR-TB is outlined and advantages and disadvantages of these guidelines discussed. The role of ofloxacin in MDR-TB is presented, with results from a study performed by the Thailand CDC showing that the percentage of strains resistant to ofloxacin was 4.3%, and to ciprofloxacin was 8.3%. The resistance to both ofloxacin and ciprofloxacin was very low at 1.4%. The percentage of cross-resistance between these fluoroquinolones was also low; 33% resistant to ofloxacin were also resistant to ciprofloxacin and only 17% of those resistant to ciprofloxacin were also resistant to ofloxacin. Results from a clinical trial evaluating ofloxacin with other drugs for MDR-TB are also reported. The regimen comprised ofloxacin 600 mg/day, pyrazinamide (PZA), two to three months of kanamycin (KM) or amikacin (AMK), para-aminosalicylic acid (PAS) plus EMB or thiacetazone. Drugs were given for 18 months. Follow-up was every three months for two years. Preliminary results revealed that the percentage of acquired MDR-TB resistant to specific agents was as follows: 36% resistant to INH and RFP, 23% resistant to INH, RFP plus EMB, 27% resistant to INH, RFP and SM, and 14% resistant to all four of these agents (INH + RFP + SM + EMB). All isolates were sensitive to ofloxacin. At one month of treatment, sputum culture conversion was approximately 25%, climbing to 93% by nine months of treatment. Treatment with ofloxacin in a combined regimen achieved a success rate of 78%. The role of quinolones in preventing TB in MDR-TB contacts is also discussed.